SunnyTan
2021-10-14
[财迷]
Why Novavax Stock Is Absurdly Cheap Right Now
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":825870568,"tweetId":"825870568","gmtCreate":1634219796081,"gmtModify":1634219796194,"author":{"id":3586693889144003,"idStr":"3586693889144003","authorId":3586693889144003,"authorIdStr":"3586693889144003","name":"SunnyTan","avatar":"https://static.tigerbbs.com/c883137e5fd3b5129ac01f4a7fd4b6bc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[财迷] </span></p></body></html>","htmlText":"<html><head></head><body><p><span>[财迷] </span></p></body></html>","text":"[财迷]","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/825870568","repostId":2175195492,"repostType":4,"repost":{"id":"2175195492","pubTimestamp":1634219004,"share":"https://www.laohu8.com/m/news/2175195492?lang=&edition=full","pubTime":"2021-10-14 21:43","market":"us","language":"en","title":"Why Novavax Stock Is Absurdly Cheap Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2175195492","media":"Motley Fool","summary":"The sell-off of this vaccine stock appears to be overdone.","content":"<p><b>Novavax</b> (NASDAQ:NVAX) has taken investors on a wild roller-coaster ride so far this year. Its shares skyrocketed more than 180% by early February. Nearly all of those gains were gone just three months later.</p>\n<p>The stock rebounded strongly, though, over the next several months. But since early September, Novavax's share price has plunged more than 35%.</p>\n<p>After all of these dizzying gyrations, Novavax appears to be the biggest bargain among the top vaccine stocks. Here's why Novavax stock is absurdly cheap right now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646091%2Fvaccine-bottles-forming-a-dollar-sign.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"375\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>An overdone sell-off</h2>\n<p>There are two primary reasons behind the recent sell-off in Novavax stock. One is the company's further delays in filing for authorizations and approvals in key markets. The other is the positive results announced by <b>Merck</b> and Ridgeback Biotherapeutics for their COVID-19 pill. Investors' reactions to both developments appear to be overdone.</p>\n<p>Novavax moving the goal post with respect to regulatory submissions is certainly disappointing. That's especially the case since the company has missed its timeline for filing for authorization multiple times. However, these delays are speed bumps instead of roadblocks.</p>\n<p>The company's safety and efficacy data for COVID-19 vaccine candidate NVX-CoV2373 are compelling. Novavax's challenge relates to resolving manufacturing issues. Those problems should be solvable.</p>\n<p>Neither Novavax nor other leading vaccine makers should be negatively impacted all that much by Merck's COVID-19 pill. Sure, some individuals could opt to forego vaccination if and when the therapy is available. However, governments across the world almost certainly won't reduce their push for their citizens to receive COVID-19 vaccines.</p>\n<h2>Simple math</h2>\n<p>The main argument for why Novavax stock is absurdly cheap right now boils down to simple math. The company could generate sales of close to $5.5 billion next year. With a current market cap of around $12.2 billion, the stock is trading at a forward price-to-sales (P/S) ratio of only 2.2.</p>\n<p>How cheap is that valuation metric? The average P/S ratio for biotech stocks earlier this year was nearly four times higher than Novavax's forward sales multiple. Even big pharma stocks trade on average at close to five times sales.</p>\n<p>And Novavax still looks like a bargain compared to other vaccine stocks as well, even with their recent declines. <b>Moderna</b>'s shares currently trade at more than six times projected 2022 sales. <b>BioNTech</b> claims a forward P/S multiple of around three.</p>\n<p>All Novavax needs to do is secure regulatory authorizations and approvals in a handful of key markets for the 2022 revenue estimates to be realized. Once it achieves those milestones, the company's supply deals will kick in.</p>\n<h2>The big question</h2>\n<p>However, Novavax faces a big question that also applies to other leading COVID-19 vaccine makers: How strong will recurring revenue be over the longer term? These stocks should trade at markedly lower valuations if COVID-19 vaccine sales plunge after a year or two.</p>\n<p>It's quite possible, though, that COVID-19 vaccination will be required on an annual basis going forward. That could especially work to Novavax's advantage.</p>\n<p>The company has already reported positive results from a late-stage study of its flu vaccine NanoFlu. It's developing a combination COVID-19/flu vaccine using NVX-CoV2373 and NanoFlu. If this combo vaccine proves to be as safe and effective as its individual components, Novavax could have a major commercial success on the way.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Is Absurdly Cheap Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Is Absurdly Cheap Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-14 21:43 GMT+8 <a href=https://www.fool.com/investing/2021/10/14/why-novavax-stock-is-absurdly-cheap-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) has taken investors on a wild roller-coaster ride so far this year. Its shares skyrocketed more than 180% by early February. Nearly all of those gains were gone just three months...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/14/why-novavax-stock-is-absurdly-cheap-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/10/14/why-novavax-stock-is-absurdly-cheap-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175195492","content_text":"Novavax (NASDAQ:NVAX) has taken investors on a wild roller-coaster ride so far this year. Its shares skyrocketed more than 180% by early February. Nearly all of those gains were gone just three months later.\nThe stock rebounded strongly, though, over the next several months. But since early September, Novavax's share price has plunged more than 35%.\nAfter all of these dizzying gyrations, Novavax appears to be the biggest bargain among the top vaccine stocks. Here's why Novavax stock is absurdly cheap right now.\nImage source: Getty Images.\nAn overdone sell-off\nThere are two primary reasons behind the recent sell-off in Novavax stock. One is the company's further delays in filing for authorizations and approvals in key markets. The other is the positive results announced by Merck and Ridgeback Biotherapeutics for their COVID-19 pill. Investors' reactions to both developments appear to be overdone.\nNovavax moving the goal post with respect to regulatory submissions is certainly disappointing. That's especially the case since the company has missed its timeline for filing for authorization multiple times. However, these delays are speed bumps instead of roadblocks.\nThe company's safety and efficacy data for COVID-19 vaccine candidate NVX-CoV2373 are compelling. Novavax's challenge relates to resolving manufacturing issues. Those problems should be solvable.\nNeither Novavax nor other leading vaccine makers should be negatively impacted all that much by Merck's COVID-19 pill. Sure, some individuals could opt to forego vaccination if and when the therapy is available. However, governments across the world almost certainly won't reduce their push for their citizens to receive COVID-19 vaccines.\nSimple math\nThe main argument for why Novavax stock is absurdly cheap right now boils down to simple math. The company could generate sales of close to $5.5 billion next year. With a current market cap of around $12.2 billion, the stock is trading at a forward price-to-sales (P/S) ratio of only 2.2.\nHow cheap is that valuation metric? The average P/S ratio for biotech stocks earlier this year was nearly four times higher than Novavax's forward sales multiple. Even big pharma stocks trade on average at close to five times sales.\nAnd Novavax still looks like a bargain compared to other vaccine stocks as well, even with their recent declines. Moderna's shares currently trade at more than six times projected 2022 sales. BioNTech claims a forward P/S multiple of around three.\nAll Novavax needs to do is secure regulatory authorizations and approvals in a handful of key markets for the 2022 revenue estimates to be realized. Once it achieves those milestones, the company's supply deals will kick in.\nThe big question\nHowever, Novavax faces a big question that also applies to other leading COVID-19 vaccine makers: How strong will recurring revenue be over the longer term? These stocks should trade at markedly lower valuations if COVID-19 vaccine sales plunge after a year or two.\nIt's quite possible, though, that COVID-19 vaccination will be required on an annual basis going forward. That could especially work to Novavax's advantage.\nThe company has already reported positive results from a late-stage study of its flu vaccine NanoFlu. It's developing a combination COVID-19/flu vaccine using NVX-CoV2373 and NanoFlu. If this combo vaccine proves to be as safe and effective as its individual components, Novavax could have a major commercial success on the way.","news_type":1},"isVote":1,"tweetType":1,"viewCount":376,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/825870568"}
精彩评论